Citadel Advisors
AEGR

Citadel Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Citadel Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-58,100
Closed -$173K – 8329
2016
Q3 		$173K Buy
58,100
+14,900
+34% +$25.8K ﹤0.01% 6400
2016
Q2 		$64K Buy
+43,200
New +$98.8K ﹤0.01% 6348
2016
Q1 		– Sell
-27,400
Closed -$277K – 8901
2015
Q4 		$277K Sell
27,400
-100
-0.4% -$1.2K ﹤0.01% 5337
2015
Q3 		$374K Sell
27,500
-11,500
-29% -$205K ﹤0.01% 5237
2015
Q2 		$740K Buy
39,000
+2,600
+7% +$56.3K ﹤0.01% 4386
2015
Q1 		$953K Sell
36,400
-4,000
-10% -$102K ﹤0.01% 3988
2014
Q4 		$846K Buy
40,400
+1,900
+5% +$47.9K ﹤0.01% 3974
2014
Q3 		$1.28M Buy
38,500
+8,600
+29% +$267K ﹤0.01% 3402
2014
Q2 		$959K Sell
29,900
-32,100
-52% -$1.2M ﹤0.01% 3552
2014
Q1 		$2.86M Buy
62,000
+35,600
+135% +$2.09M ﹤0.01% 2269
2013
Q4 		$1.87M Sell
26,400
-13,600
-34% -$1.04M ﹤0.01% 2610
2013
Q3 		$3.43M Buy
40,000
+7,200
+22% +$610K 0.01% 1910
2013
Q2 		$2.08M Buy
+32,800
New +$1.74M ﹤0.01% 2458

Citadel Advisors's AEGR Position: Q4 2016 in Review

Citadel Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 21,603 shares — an estimated $64K sold.

Citadel Advisors first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $3.27M in Q2 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Citadel Advisors reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Citadel Advisors sold 21,603 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $64K.
  • Citadel Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Citadel Advisors's Aegerion Pharmaceuticals position peaked at $3.27M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.